Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy Metastatic Non-Small Cell Lung Cancer
Rizvi N, Antonia S, Shepherd F, Chow L, Goldman J, Shen Y, Chen A, Gettinger S. Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy Metastatic Non-Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s32. DOI: 10.1016/j.ijrobp.2014.08.206.Peer-Reviewed Original Research